A randomised, open, parallel-group, multicentre study to examine the safety and effectiveness of three doses of argatroban as anticoagulant in combination with clopidogrel and aspirin in patients undergoing elective percutaneous coronary intervention in comparison with unfractionated heparin, clopidogrel and aspirin

Trial Profile

A randomised, open, parallel-group, multicentre study to examine the safety and effectiveness of three doses of argatroban as anticoagulant in combination with clopidogrel and aspirin in patients undergoing elective percutaneous coronary intervention in comparison with unfractionated heparin, clopidogrel and aspirin

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Argatroban; Aspirin; Clopidogrel; Heparin
  • Indications Coronary artery disease; Thrombosis; Unstable angina pectoris
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mitsubishi Pharma Corporation
  • Most Recent Events

    • 14 Apr 2011 Results published in the International Journal of Cardiology.
    • 03 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top